glp-1 va Semaglutide in Virginia Beach, Virginia va glp 1 study GLP-1

Key Highlights Three once-monthly injections achieved placebo-adjusted weight loss of up to 6.3% at Week 12, increasing to 7.5% at Week 16 Weight loss maintained up to 4 months after the final dose, supporting once-quarterly maintenance therapy potential No weekly lead-in dosing required, differentiating ASC30 from many current GLP-1 regimens Safety profile consistent with the GLP-1 class, with mild-to-moderate adverse events and no discontinuations Why It Matters: Convenience advantage: Monthly or quarterly dosing could significantly improve adherence vs weekly GLP-1 injections Small-molecule innovation: ASC30 is a GLP-1 biased small molecule, enabling both oral and injectable formulations Platform validation: Supports Ascletis Ultra-Long-Acting Platform (ULAP) for developing long-duration metabolic therapies Key Takeaway: ASC30 highlights the next frontier in obesity therapeuticsultra-long-acting incretin therapies

Remember: Zepbound is a long-term medication for weight loss that works best when you make other lifestyle changes like diet and exercise

This is a reason to exercise caution when prescribing in patients who already have pre-existing gastroparesis, which is common in patients who have type 2 diabetes

Exenatide and Metformin express their anti-inflammatory effects on human monocytes/macrophages by the Attenuation of MAPKs and NFB signaling